Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is experiencing robust momentum with its leading product, Cabometyx, particularly in the first-line renal cell carcinoma (RCC) market, where it has achieved a 46% market share, reflecting a year-over-year growth of 15% in total prescription volume. The company is also expanding its gastrointestinal sales team to capitalize on the growing demand for Cabometyx and to prepare for the launch of zanzalintinib in colorectal cancer (CRC), which has shown promising results in the Phase 3 STELLAR-303 trial. Furthermore, Exelixis is set to benefit from a strong balance sheet and sustainable profitability, with revised sales estimates for Cabometyx indicating a positive growth trajectory through fiscal years 2026 to 2028.

Bears say

Exelixis Inc's recent financial performance indicates challenges, particularly with a gross-to-net (GTN) decrease from 30.2% to 28.5% in 4Q25, negatively influenced by lower PHS/340B volumes. Additionally, Cabometyx sales reached $545 million in 4Q25, falling short of consensus estimates which anticipated higher revenues, thereby raising concerns about future growth in a competitive market for renal and hepatocellular carcinoma treatments. The company faces various risks, including commercial pressures on Cabometyx, potential lack of positive clinical trial data, and the threat of generic competition, which collectively contribute to a diminished outlook for the stock.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.